Originally published Nov. 6.

Myriad Genetics will combine its Comprehensive BRACAnalysis test and BRCA large rearrangement testing into one commercial product, but continue to price it as two separate offerings, company officials told analysts during a call discussing first-quarter financials for the firm's 2013 fiscal year.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.